Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carfilzomib + Tinostamustine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carfilzomib||Kyprolis||PR-171||Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov).|
|Tinostamustine||EDO-S101|EDOS101|EDO S101||Chemotherapy - Alkylating 16 HDAC Inhibitor 42||Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594, PMID: 32099034, PMID: 31372848).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|